HFM
TEVA icon

Hartford Financial Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hartford Financial Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$1K – 392
2021
Q3 		$1K Hold
100
– – ﹤0.01% 390
2021
Q2 		$1K Hold
100
– – ﹤0.01% 372
2021
Q1 		$1K Hold
100
– – ﹤0.01% 383
2020
Q4 		$1K Buy
+100
New +$958 ﹤0.01% 349
2018
Q1 		– Sell
-600
Closed -$11K – 359
2017
Q4 		$11K Hold
600
– – 0.01% 266
2017
Q3 		$10K Hold
600
– – 0.01% 299
2017
Q2 		$19K Hold
600
– – 0.01% 234
2017
Q1 		$19K Hold
600
– – 0.01% 226
2016
Q4 		$22K Sell
600
-35
-6% -$1.4K 0.01% 186
2016
Q3 		$29K Hold
635
– – 0.02% 184
2016
Q2 		$31K Buy
+635
New +$33.8K 0.02% 168

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hartford Financial Management's TEVA Position: Q4 2021 in Review

Hartford Financial Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 100 shares — an estimated $1K sold.

Hartford Financial Management first reported a position in TEVA in Q2 2016 and held it in 11 quarters. The position peaked at $31K in Q2 2016. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Hartford Financial Management reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Hartford Financial Management sold 100 Teva Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Hartford Financial Management first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 11 quarters.
  • Hartford Financial Management's Teva Pharmaceuticals position peaked at $31K in Q2 2016.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Hartford Financial Management's 13F filing for Q4 2021, filed 27 Jan 2022.